A holding company manages an early-stage life sciences fund focused exclusively on private companies developing pharmaceutical products. The firm invests globally in early-stage programs, preferably with proof-of-concept validation, and supports companies from venture creation through Series A.
Investments are made in the form of straight equity, with capital deployed over the life of the company. The firm is science-driven, may lead or co-invest, seeks board representation, and takes an active role in guiding company development and strategy. The firm does not target a fixed number of investments per year.
In addition to the early-stage strategy, the firm also manages a late-stage vehicle focused on private pharmaceutical companies raising Series B through crossover or IPO rounds.
Across both strategies, the firm is open to preclinical and clinical-stage therapeutic companies and is agnostic to modality and indication. The firm invests exclusively in first-in-class, breakthrough assets and does not consider repurposed drugs, diagnostics, medical devices, or incremental technologies.
The firm prefers to invest early and support companies through major value inflection points. The firm does not impose specific requirements regarding management team composition.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment